Income from Continuous Operations: A company's total income or loss before discontinued operations, extraordinary items, preferred stock dividends and accounting change.
SpyGlass Pharma, Inc. (SGP) had Income from Continuous Operations of -39.87M for the most recently reported fiscal year, ending 2025-12-31.
| Income Statement Financials | |
-- |
|
-39.87M |
|
-- |
|
-- |
|
41.45M |
|
-41.45M |
|
1.58M |
|
-39.87M |
|
-39.87M |
|
-39.87M |
|
|
Income from Continuous Operations |
-39.87M |
-39.87M |
|
-39.87M |
|
-41.45M |
|
-40.84M |
|
2.22M |
|
2.22M |
|
-17.98 |
|
-17.98 |
|
| Balance Sheet Financials | |
108.77M |
|
2.34M |
|
7.10M |
|
115.87M |
|
8.58M |
|
-- |
|
206.12M |
|
214.70M |
|
-98.84M |
|
-98.84M |
|
-98.84M |
|
2.20M |
|
| Cash Flow Statement Financials | |
-32.70M |
|
-11.79M |
|
124.58M |
|
16.27M |
|
96.36M |
|
80.09M |
|
2.79M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
12.67 |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-33.49M |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
40.34% |
|
40.34% |
|
-34.41% |
|
40.34% |
|
-44.84 |
|
-15.11 |
|
-14.75 |
|